Abstract:Monoclonal antibodies are of great use in research and clinic. The first monoclonal antibody production method, hybridoma technology, was marked in the paper "Continuous cultures of fused cells secreting antibody of predefined specificity" by Milstein and Kohler in 1975 in Nature. Based on that paper, we took a retrospective and forward look of this technique. In the early research of antibodies and B cells, the low specificity and bad reproductivity of polyclonal antibodies called for new methods to produce highly specific antibodies. Fortunately, the scientists encountered the key prerequisites of the hybridoma method: (1) Mouse multiple myeloma cell lines, which can secrete antibodies and infinitely reproduce in vitro; (2) SRBC (sheep red blood cell) plates that can screen the cells secreteing anti-SRBC antibodies; (3) proper cell fusion methods like Sendai virus and PEG. Based on all these materials and methods, Milstein and Kohler fused spleen cells of immunized mice with mouse myeloma cell line P3-X67Ag8 by inactivated Sendai virus and screened to clone the fused cells that can secrete anti-SRBC antibodies. They also used HAT medium to ensure that only fused cells from spleen cells and myeloma cells can survive. In this way, they obtained the immortal cells that can produce a single type of antibody with a predefined antigen-specificity, or say, hybridoma cells that can produce monoclonal antibodies. This powerful tool of hybridoma was quickly applied and improved. Milstein and Kohler were awarded the Nobel prize and Lasker award in 1984. Despite the great commercial potential of hybridoma in medication and science research, Milstein and Kohler did not patent the method, making it free to use by anyone in the world. The monoclonal antibodies produced by hybridoma were proved highly versatile in the laboratory. Besides great insights provided to us in basic immunology research, they become the indispensable tool to precisely qualify, quantify, and localize macromolecule in all fields of research. Fluorescence imaging, Western blotting, flow cytometry and microarray methods all make use of monoclonal antibodies. Upon chimera, humanized and human monoclonal antibody development, the application and success of monoclonal antibodies on the biopharma market are even greater. Monoclonal antibody medicines to treat cancer and autoimmune diseases are making billions of dollars every year. Notably, among these medicines, anti-PD-1 and anti-CTLA-4 are awarded Nobel prize in 2018 as anti-tumor immune checkpoint inhibitors. Monoclonal antibody medicines for contagious diseases like Ebola also shows advantages over others. For the new outbreak of COVID-19 around the world, monoclonal antibodies are also promising in offering new cures. Presently, the production of monoclonal antibodies is no longer solely dependent on hybridoma technology. Transgenic and recombinant DNA technology are creating new possibilities in this ever-growing field.

Immunogenicity of monoclonal antibody: Causes, consequences, and control strategies

The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies

Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies

Monoclonal antibodies: From magic bullet to precision weapon

The role of therapeutic antibodies in drug discovery

Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy

Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework

Current Strategy of Monoclonal Antibody: Development, Cloning, Formulation and Drug Delivery

Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations

The history of monoclonal antibody development – Progress, remaining challenges and future innovations

Drug Development of Therapeutic Monoclonal Antibodies

Production of monoclonal antibodies for therapeutic purposes: A review

Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics

Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview

Opportunities and Challenges of Therapeutic Monoclonal Antibodies As Medical Countermeasures for Biodefense

Therapeutic Antibodies and Immunologic Conjugates

The impact of monoclonal antibodies in preventing antimicrobial resistance (AMR)

Monoclonal Antibodies: Emergence, Present and Outlook

Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes

Building better monoclonal antibody-based therapeutics

T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics